The phase 3 TENAYA and LUCERNE trials, which assessed the safety and efficacy of faricimab for wet AMD therapy, have wrapped up. What did the researchers learn? New Retina Radio spoke with Arshad Khanani, MD, MA, about his ARVO presentation on these trials. We also spoke with David Lally, MD, whose ARVO presentation adds new data to the great fluid debates in wet AMD. What did his research team uncover that can inform our understanding of fluid dynamics in these patients?  

This editorially independent podcast is supported with advertising.